论文部分内容阅读
Hoffmann－LaRoche公司的单克隆抗体rituximab（商品名MabThera）获欧联盟许可用于治疗复发的或难治性滤泡B细胞非霍奇金淋巴瘤。本品是用于这一适应证的第一个单克隆抗体。本品已在所有欧盟国家获得使用许可；预计将在英国和德国首先上市，不久之后在其它成员国上市。单克隆抗
Hoffmann-LaRoche’s monoclonal antibody rituximab (trade name MabThera) has been approved by the European Union for the treatment of relapsed or refractory follicular B-cell non-Hodgkin’s lymphoma. This product is the first monoclonal antibody used for this indication. This product has been licensed for use in all EU countries; it is expected to be listed first in the UK and Germany, and soon thereafter in other member states. Monoclonal antibody